Pharmaceutical Technology Europe, Apr 1, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology Europe, Apr 1, 2011
Editor's Comment
From Tokyo with love
By Rich Whitworth
Having spent the last five years of my life in Tokyo, I wanted to start this month's Editor's comment by offering my very deepest sympathy to all those who have been affected by the earthquake and tsunami in Japan.
Special Feature
Tabletting: Expert Views
By Dale Natoli , Sophie Chesnoy , Chris Prideaux
Pharmaceutical Technology Europe brings together suppliers of tabletting equipment and excipients to discuss the challenges, innovations and latest trends in the tabletting industry.
Ensuring Tabletting Saftey For High Potency APIs
By Jan Vogeleer
The main challenge for tablet manufacturers processing highly potent APIs (HPAPIs) is to protect equipment operators from the inhalation of airborne particles and prevent skin contact with the product during the entire production process: dispensing, granulation, tablet compression, coating and packaging.
Manufacturing
Review of FDA Warning Letters
By Jeanne Moldenhauer
The author reviews Warning Letters issued between 2000 and mid-2010 for aseptic processing and non-sterile processing, and determines how many observations were made for each section of the GMPs.
Analytical
Challenges Of Particle Characterisation
By Victoria Jones
Particle characteristics can affect pharmaceutical formulations and products in a number of ways, and a variety of techniques are available that enable particle monitoring and characterisation.
Industry Insider
Reforming The Approach To Pharmacovigilance In Europe
By Nathan Jessop
Europe's approach to pharmacovigilance has room for improvement that European agencies are working on.
News
News
A round up of European news.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here